Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 5/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | GCLC | P48506 | 1/20 | 0.33 |
| ▸ | GGH | Q92820 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871610 | 0.81 | FOLH1 (0.45) | FOLH1CA2LAP3GGHGRM3 | |
| SCHEMBL21059309 | 0.81 | LAP3 (0.37) | FOLH1LAP3PGK1PGK2GCLC | |
| SCHEMBL12473689 | 0.81 | PGK1 (0.36) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL3908397 | 0.81 | PPARD (0.38) | FOLH1LAP3PGK1PGK2 | |
| SCHEMBL6579012 | 0.80 | LMNA (0.38) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL28156892 | 0.79 | PGK1 (0.35) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL2984496 | 0.78 | MMP1 (0.33) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL3471393 | 0.77 | FOLH1 (0.40) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL2988982 | 0.77 | FOLH1 (0.43) | FOLH1MMP1MMP2CA12CA1 | |
| SCHEMBL1960686 | 0.77 | FOLH1 (0.54) | FOLH1MMP1MMP2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554330-B1 | PARTIALLY ESTER-EXCHANGED SIPM AND PROCESS THEREWITH | INVISTA TECH SARL (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-1615934-B1 | TITANIUM CHELATE DISPERSIONS | DU PONT (US) | 2007-06-27 | — | — | EP | claimed |
| US-10774098-B2 | Nahlsgen optical resolution method | KYOTO UNIVERSITY (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | KYOTO UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | HACL2, HAO2, HPD | FOLH1 1164/4885MMP1 1524/4885MMP2 4215/4885 |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | HACL2, HAO2, HPD | FOLH1 1164/4885MMP1 1524/4885MMP2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.